Paricalcitol en es it fr

Paricalcitol Brand names, Paricalcitol Analogs

Paricalcitol Brand Names Mixture

  • No information avaliable

Paricalcitol Chemical_Formula

C27H44O3

Paricalcitol RX_link

http://www.rxlist.com/cgi/generic4/zemplar_caps.htm

Paricalcitol fda sheet

Paricalcitol FDA

Paricalcitol msds (material safety sheet)

Paricalcitol Synthesis Reference

No information avaliable

Paricalcitol Molecular Weight

416.636 g/mol

Paricalcitol Melting Point

No information avaliable

Paricalcitol H2O Solubility

No information avaliable

Paricalcitol State

No information avaliable

Paricalcitol LogP

4.031

Paricalcitol Dosage Forms

Solution

Paricalcitol Indication

For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4

Paricalcitol Pharmacology

Secondary hyperparathyroidism is characterized by an elevation in parathyroid hormone (PTH) associated with inadequate levels of active vitamin D hormone. The source of vitamin D in the body is from synthesis in the skin and from dietary intake. Vitamin D requires two sequential hydroxylations in the liver and the kidney to bind to and to activate the vitamin D receptor (VDR). The endogenous VDR activator, calcitriol [1,25(OH)2 D3], is a hormone that binds to VDRs that are present in the parathyroid gland, intestine, kidney, and bone to maintain parathyroid function and calcium and phosphorus homeostasis, and to VDRs found in many other tissues, including prostate, endothelium and immune cells. VDR activation is essential for the proper formation and maintenance of normal bone. In the diseased kidney, the activation of vitamin D is diminished, resulting in a rise of PTH, subsequently leading to secondary hyperparathyroidism and disturbances in the calcium and phosphorus homeostasis.1 Decreased levels of 1,25(OH)2 D3 have been observed in early stages of chronic kidney disease. The decreased levels of 1,25(OH)2 D3 and resultant elevated PTH levels, both of which often precede abnormalities in serum calcium and phosphorus, affect bone turnover rate and may result in renal osteodystrophy. An in vitro study indicates that paricalcitol is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A at concentrations up to 50 nM (21 ng/mL).

Paricalcitol Absorption

well absorbed

Paricalcitol side effects and Toxicity

No information avaliable

Paricalcitol Patient Information

No information avaliable

Paricalcitol Organisms Affected

Humans and other mammals